Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell lymphoma and chronic lymphocytic leukemia; FT538 to treat AML and multiple myeloma; FT576 to treat multiple myeloma; FT819 to treat hematologic malignancies and solid tumors; FT536 to treat solid tumors; and FT500 for the treatment of advanced solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of two off-the-shelf iPSC-derived CAR T-cell product candidates; strategic research collaboration and license agreement with Juno Therapeutics, Inc. to screen for and identify small molecule modulators that enhance the therapeutic properties of genetically-engineered T-cell immunotherapies; and a collaboration and option agreement with Janssen Biotech, Inc. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.
P/B ratio for Fate Therapeutics, Inc. (FATE)
P/B ratio as of 2023: 1.00
According to Fate Therapeutics, Inc.'s latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 1.00. At the end of 2022 the company had a P/B ratio of 2.02.
P/B ratio history for Fate Therapeutics, Inc. from 2011 to 2023
P/B ratio at the end of each year
| Year | P/B ratio |
|---|---|
| 2023 | 1.00 |
| 2022 | 2.02 |
| 2021 | 8.17 |
| 2020 | 19.49 |
| 2019 | 5.45 |
| 2018 | 4.49 |
| 2017 | 3.32 |
| 2016 | 1.09 |
| 2015 | 2.26 |
| 2014 | 3.63 |
| 2013 | 0.73 |
| 2012 | -1.11 |
| 2011 | -1.16 |